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SUMMARY – Gastrointestinal stromal tumors (GIST) are the most common mesenchymal 
 tumors of the digestive tract and are generally asymptomatic. A 39-year-old female patient was hos-
pitalized in 2012 at Clinical Department of Internal Medicine, Sestre milosrdnice University Hospi-
tal Center, for a focal hypodense irregular circular lesion located in segment III of the left hepatic lobe, 
accidentally found by ultrasonography and verifi ed by computed tomography. Th e fi ndings were also 
verifi ed with nuclear magnetic resonance and esophagogastroduodenoscopy. A biopsy sample of the 
lesion was analyzed by histologic and immunohistochemical methods and identifi ed as GIST. Th e 
patient underwent surgical operation (tumor excision with terminoterminal anastomosis  created 
 between the second segment of duodenum and jejunum and resection of liver segment III). Th e 
 histopathologic fi ndings matched GIST with a high probability of relapse according to the  localization, 
size, mitotic activity and Ki-67 values. Th erefore, therapy with imatinib at a dose of 400 mg/day was 
administered. Th ree years after the operation, the patient is still in remission.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the 
most common mesenchymal tumors of the digestive 
tract and are generally asymptomatic, but they make 
only 1% of primary tumors of the gastrointestinal (GI) 
tract. GISTs are usually accidentally found during 
 endoscopic or radiologic procedures. After immuno-
histochemical analysis, Hirota et al.1 discovered con-
nection between GIST and Cajal intestinal cells and 
their predecessors. Th e incidence of GIST is 6.8-14.5/
million2-5, it occurs at a median age of 63 and men are 
aff ected more commonly (55%). In 80% of cases, 
a KIT-gene mutation is found, 15% are considered 
as a wild-type mutation and 5% are KIT-negative 
PDFRA-positive mutation6. Th e two most common 
primary sites are stomach (60%-75%) and small intes-
tine (20%-30%). GIST shows extraluminal growth, 
but it does not infi ltrate local organs. About 10%-25% 
of patients have metastases, most common in the liver 
and peritoneum. Diagnostic algorithm consists of 
multi-slice computed tomography (MSCT), magnetic 
resonance imaging (MRI), ultrasonography, endo-
scopic ultrasonography, positron emission tomogra-
phy-computed tomography (PET CT), histopatho-
logic and immunohistochemical methods. Primary 
treatment is surgical procedure with adjuvant pharma-
cotherapy with imatinib.
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Case Report
A 39-year-old female patient treated for iron-defi -
ciency anemia since 2006 was hospitalized in 2012 at 
Clinical Department of Internal Medicine, Sestre mi-
losrdnice University Hospital Center. She came from 
another facility for planned aspiration biopsy of CT-
verifi ed focal hypodense irregular circular lesion with 
an approximately 3-cm diameter located in segment 
III of the left hepatic lobe. Transabdominal ultrasound 
(Fig. 1a, b) revealed a tumorous ring-shaped lesion, in 
addition to prior CT-verifi ed lesion, with a diameter 
of 42 mm on the right paravertebral side in the projec-
tion of the duodenum, which was confi rmed by nucle-
ar MRI (Fig. 2a, b). Her symptoms in the past 6 
months were postprandial pain in the right upper 
quadrant and weight loss (5 kg). She had slightly low-
er hemoglobin, hematocrit and mean corpuscular vol-
ume (MCV) with slightly elevated alfa 1 protein in 
plasma electrophoresis. Esophagogastroduodenoscopy 
(EGD) of the postbulbar duodenal segment (transi-
tion between segment II and segment III) was per-
formed and showed a circular yellowish proliferative 
lesion which narrowed down the lumen to about 10 
mm. A biopsy sample of the lesion was analyzed by 
histologic and immunohistochemical methods and 
identifi ed as GIST (Fig. 3a, b). An operation was per-
Fig. 1a. Upper abdomen ultrasonography showing 
an irregularly round focal hypoechoic lesion, 38 mm 
in diameter, and a ventral anechoic area in the left 
hepatic lobe.
Fig. 1b. Upper abdomen ultrasonography showing 
a ring-shaped tumor mass, 42 mm in diameter, 
paravertebrally right.
Fig. 2a. Nuclear magnetic resonance imaging 
of the abdomen showing an expansive mass, 32 mm 
in diameter, in the left hepatic lobe (border of the 2nd 
and 3rd segment), which caused deformity of the liver 
and had high intensity T2 signal centrally (necrosis 
or liquid content).
Fig. 2b. Nuclear magnetic resonance imaging of the 
abdomen: in the projection of the fi rst part of duodenum, 
the wall is thickened (10-20 mm) and has irregular shape 
with transverse diameter of 45 mm; on the right, 
parapielic cyst with diameter of 50 mm.
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formed (5 cm large tumor excision and resection of 
segment III, segment IV and partial resection of distal 
segment II of duodenum with terminoterminal anas-
tomosis created between second segment of duode-
num and jejunum and resection of liver segment III). 
Th e histopathologic fi ndings matched GIST with a 
high probability of relapse according to the localiza-
tion, size, mitotic activity and Ki-67 values. Th erefore, 
therapy with imatinib at a dose of 400 mg/day was 
administered. Th ree years after the operation, the pa-
tient is still in remission.
Discussion
Abdominal ultrasonography and EGD are men-
tioned as primary diagnostic methods in GIST diag-
nostics. Th ey are usually performed because of abdom-
inal pain or palpable masses within the abdomen. 
When the initial suspicion of GIST is set, MSCT is 
the main imaging method for diagnosing both pri-
mary tumor and possible metastases, but sometimes 
GIST can be suspected just on ultrasonography. PET 
CT can be useful in determining hidden metastases7, 
but GIST may be present without signifi cant meta-
bolic activity. EGD is used to describe tumor mor-
phology, possible strictures in the GI tract, and to take 
biopsy samples. In our case, postbulbar duodenum was 
infi ltrated with a circular, yellowish lesion which nar-
rowed it to 0.8 cm. Endoscopic ultrasonography (EUS) 
is the best method to diff erentiate GIST from leio-
myoma. Leiomyoma and GIST have their origin in 
the 2nd and 4th hypoechoic layer, respectively. GIST has 
distorted shape, lobulation, irregular borders and in-
creased echogenicity in comparison with the sur-
rounding muscle echo, inhomogeneous pattern (inho-
mogeneity, hyperechoic posts, anechoic area), marginal 
halo and extraluminal growth pattern. Other signs 
that indicate malignancy are tumors bigger than 3 cm 
with irregular edges. In addition to EUS, EUS elastog-
raphy with dominantly quantitative analysis (relatively 
heterogeneous ‘hard’ appearance without display of ar-
eas of necrosis by elastography software) can be per-
formed and the strain ratio index measured. GIST has 
a high strain ratio index and therefore cannot be com-
pressed. Contrast-enhanced EUS (CE-EUS) can 
demonstrate perfusion characteristics of subepithelial 
lesion and therefore can be used to diff erentiate GIST 
from other benign tumors (lipoma or leiomyoma) 
based on the hyper-enhanced appearance of GIST. 
CE-EUS has been recently used for assessment of tu-
mor vascularity in order to predict the preoperative 
malignancy risk of GISTs through identifi cation of ir-
regular vessels. With the EUS method, safe thin-nee-
dle biospy can be performed8 to obtain samples for 
histopathologic and molecular analysis. Table 1 shows 
complete histologic analysis of GIST.
After that, classifi cation of stages and risk determi-
nation according to one of the classifi cations must be 
done. All these classifi cations have a purpose to deter-
mine high, intermediate or low risk GIST. According 
Fig. 3a. Part of the tumor mass that contains elongated 
cells with pale eosinophilic cytoplasm, elongated nuclei 
and partly present perinuclear vacuoles located at the poles 
of the nuclei; 17 mitoses per 50 HPF. (HE, X400)
Fig. 3b. Histologic image of tumor mass on 
immunohistochemical procedure (CD117+, CD34+, 
PDGFr-, S100-, SMA-, desmin-). (CD 117, X400)
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Table 1. Complete histologic analysis of gastrointestinal 
stromal tumors
Content of histologic analysis Our patient
Diagnosis and classifi cation according 
to histologic cell type 
Spindle cell
Size of tumor 5 cm




Number of mitoses/50 VVP 15/50 
Proliferation index (Ki in %) 17%
c-KIT (focal/diff use positive, negative, 
dot-like positive in cytoplasm)
Diff use/
+(positive)
DOG1 (focal/diff use positive, negative) -(negative)
CD34 (focal/diff use positive, negative)
 Diff use/
+(positive)
Desmin (focal/diff use positive, negative) -(negative)
SMA (focal/diff use positive, negative) -(negative)
S-100 (focal/diff use positive, negative) -(negative)
Ki-67 (% of positive cells) 17%
to the US National Institutes of Health, 44% of GIST 
are high risk, 23.6% intermediate risk and 32.4% low 
risk. In our case, the patient was classifi ed in the high 
risk group.
Treatment of GIST is multidisciplinary through 
cooperation of surgeon, pathologist and oncologist9,10. 
Complete surgical removal is recommended. In the 
treatment of inoperable or metastatic GIST, imatinib 
at a dose of 400 mg/day is used. In case of disease pro-
gression, the dose can be increased to 800 mg/day of 
imatinib. In patients with high and intermediate risk 
GIST, 400 mg/day imatinib therapy is recommended, 
as in our patient. In patients with inoperable or meta-
static imatinib-resistant GIST, sutinib11 can be used as 
second line therapy. Th ere are other promising drugs in 
clinical trials such as nilotinib, masitinib, dasatinib, 
sorafenib, vatalanib and combination of imatinib with 
RAD001-everolimus12,13.
Conclusion
Gastrointestinal stromal tumors are rare tumors of 
the gastrointestinal tract, which account for only 1% of 
all primary tumors of the GI tract14,15, and they are of-
ten diagnosed accidentally. Initial suspicion of GIST 
can be set by ultrasonography, but the main diagnostic 
methods are MSCT and EUS16.
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Sažetak
ULTRAZVUK ABDOMENA – VODEĆA METODA U DIJAGNOSTICI GIST-a DUODENUMA 
S. Bohnec, I. Budimir, D. Hrabar, N. Babić, I. Budimir ml., M. Nikolić i I. Pavić
Gastrointestinalni stromalni tumori (GIST) najčešći su mezenhimni tumori probavnog trakta i najčešće su asimptomat-
ski. Naša 39-godišnja bolesnica hospitalizirana je 2012. godine na Klinici za internu medicinu KBC-a Sestre milosrdnice 
zbog ultrazvučno slučajno nađene i kompjutorskom tomografi jom potvrđene hipodenzne nepravilne okrugle lezije lokalizi-
rane u 3. segmentu lijevog jetrenog režnja. Nalaz je potvrđen magnetskom rezonancijom i ezofagogastroduodenoskopijom. 
Histološkim i imunohistološkim metodama obrade uzorak biopsije se identifi cirao kao GIST. Učinjena je primarna resek cija 
(potpuna ekscizija tumora s terminoterminalnom anastomozom između II. odsječka dvanaesnika i jejunuma i resekcijom 3. 
segmenta jetre). Patohistološki nalaz je potvrdio dijagnozu GIST-a, a s obzirom na lokalizaciju, veličinu, mitotsku aktivnost 
i vrijednosti Ki-67 tumor je svrstan u skupinu visokorizičnih za recidiv. Zbog toga je indicirana terapija imatinibom u dozi 
od 400 mg/dan. Tri godine nakon operacije bolesnica je i dalje u remisiji.
Ključne riječi: Gastrointestinalni stromalni tumori – dijagnostika; Ultrazvuk; Elastografski slikovni prikaz; Imatinib mesilat; 
Prikazi slučaja
